Non-specific biomolecular interfaces

Non-specific biomolecular interfaces represent the physical boundaries where biological entities interact through non-selective forces such as hydrophobic effects, electrostatic interactions, and van der Waals forces (Nature Reviews Molecular Cell Biology, 2014). Unlike traditional drug targets like receptors or enzymes that rely on specific lock-and-key binding, these interfaces are characterized by low-affinity, high-avidity interactions that govern phenomena such as macromolecular crowding and liquid-liquid phase separation (Annual Review of Biophysics, 2013). In a therapeutic context, these interfaces are often viewed as obstacles or off-targets because non-specific binding (NSB) can significantly reduce the efficacy of monoclonal antibodies and small molecules, leading to poor biodistribution and increased toxicity (Journal of Pharmaceutical Sciences, 2015). However, they are also central to the pathology of neurodegenerative diseases, where the breakdown of regulated non-specific interactions leads to the formation of toxic protein aggregates, such as amyloid-beta plaques or tau tangles (Nature, 2017). Current pharmacological interventions targeting these interfaces include the use of excipients like Poloxamer 188 to stabilize membranes or the development of chaperone-like small molecules designed to prevent aberrant phase transitions (Trends in Pharmacological Sciences, 2018). Understanding these interfaces is crucial for the design of soft materials in drug delivery and for mitigating the risks of non-specific adsorption in diagnostic assays.

Other names

Non-specific binding sitesBio-interfacesNon-specific protein-protein interactionsHydrophobic interfacesNon-specific adsorptionNon-specific membrane interactions

Modulation of surface tension, steric hindrance of hydrophobic patches, and stabilization of protein solubility to prevent non-specific aggregation.